I 
Immuno-Biological Laboratories Co 4570.T · JPY
Health Care · Tokyo Stock Exchange · 🇯🇵 Japan
927
+1.31%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in JPY, from our data supplier.
Revenue
¥1.00bn
FY2017FY2026
Net income
¥329.0m
FY2017FY2026
Free cash flow
¥267.7m
FY2017FY2026
Shareholders' equity
¥1.84bn
FY2017FY2026
Income statement
Fiscal years
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ¥1.00bn | ¥969.5m | ¥816.7m | ¥794.6m | ¥647.6m | ¥602.7m | ¥576.0m | ¥781.2m | ¥758.3m | ¥741.5m |
| Gross profit | ¥700.3m | ¥628.3m | ¥517.3m | ¥526.7m | ¥376.7m | ¥346.9m | ¥216.0m | ¥460.3m | ¥477.0m | ¥414.8m |
| Research and development | ¥120.0m | ¥119.0m | ¥130.0m | ¥179.7m | ¥188.6m | ¥267.1m | ¥318.0m | ¥236.7m | ¥173.0m | ¥1.24bn |
| Operating income | ¥281.3m | ¥210.2m | ¥105.3m | ¥58.4m | −¥250.0m | −¥240.0m | −¥659.0m | −¥173.7m | −¥48.8m | −¥2.08bn |
| Net income | ¥329.0m | ¥249.0m | ¥186.7m | −¥289.7m | −¥258.8m | −¥318.8m | −¥668.0m | −¥167.3m | −¥52.6m | −¥2.09bn |
| Diluted earnings per share | 35.33 | 26.74 | 20.05 | -31.11 | -27.78 | -34.23 | -71.72 | -19.18 | -6.16 | -280.46 |
Balance sheet
At each fiscal year end
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | ¥2.16bn | ¥1.85bn | ¥1.62bn | ¥1.43bn | ¥1.71bn | ¥1.84bn | ¥3.33bn | ¥2.99bn | ¥3.30bn | ¥3.43bn |
| Cash and short-term investments | ¥989.5m | ¥825.7m | ¥734.1m | ¥614.2m | ¥508.4m | ¥604.2m | ¥1.03bn | ¥1.54bn | ¥2.51bn | ¥2.57bn |
| Total liabilities | ¥311.7m | ¥332.0m | ¥354.3m | ¥355.7m | ¥337.0m | ¥208.8m | ¥1.38bn | ¥842.5m | ¥1.28bn | ¥2.08bn |
| Debt | ¥177.1m | ¥204.2m | ¥236.0m | ¥235.0m | ¥234.0m | ¥90.0m | ¥306.0m | ¥692.7m | ¥1.13bn | ¥1.99bn |
| Shareholders' equity | ¥1.84bn | ¥1.51bn | ¥1.27bn | ¥1.08bn | ¥1.37bn | ¥1.63bn | ¥1.95bn | ¥2.15bn | ¥2.02bn | ¥1.34bn |
| Shares outstanding | 9m | 9m | 9m | 9m | 9m | 9m | 9m | 9m | 9m | 7m |
Cash flow
Fiscal years
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | ¥301.1m | ¥183.5m | ¥133.8m | ¥26.5m | −¥93.2m | −¥194.1m | −¥608.0m | −¥243.0m | ¥73.0m | −¥55.0m |
| Capital spending | −¥33.4m | −¥59.7m | −¥18.7m | — | — | −¥13.5m | −¥13.0m | −¥13.0m | −¥13.0m | −¥398.0m |
| Free cash flow | ¥267.7m | ¥123.8m | ¥115.1m | ¥26.5m | −¥93.2m | −¥207.6m | −¥621.0m | −¥256.0m | ¥60.0m | −¥453.0m |
| Dividends paid | — | — | — | — | — | — | — | — | — | −¥5,000 |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | ¥286.0m | ¥262.8m | ¥256.7m | ¥274.0m | ¥211.5m | ¥289.4m | ¥236.0m | ¥215.0m |
| Gross profit | ¥222.6m | ¥175.3m | ¥191.0m | ¥188.6m | ¥152.1m | ¥193.9m | ¥161.0m | ¥125.0m |
| Operating income | ¥117.8m | ¥57.9m | ¥81.3m | ¥87.7m | ¥54.4m | ¥84.7m | ¥56.0m | ¥17.0m |
| Net income | ¥100.3m | ¥80.8m | ¥106.6m | ¥80.7m | ¥60.9m | ¥115.7m | ¥62.0m | ¥20.0m |
| Diluted earnings per share | 10.76 | 8.68 | 11.44 | 8.66 | 6.54 | 12.42 | 6.66 | 2.15 |
| Total assets | ¥2.23bn | ¥2.16bn | ¥2.09bn | ¥1.97bn | ¥1.92bn | ¥1.85bn | ¥1.70bn | ¥1.65bn |
| Cash and short-term investments | ¥907.9m | ¥989.5m | ¥893.3m | ¥955.3m | ¥903.7m | ¥825.7m | ¥753.3m | ¥730.8m |
| Debt | ¥154.4m | ¥177.1m | ¥164.4m | ¥189.7m | ¥169.1m | ¥204.2m | ¥165.1m | ¥197.1m |
| Shareholders' equity | ¥1.89bn | ¥1.84bn | ¥1.76bn | ¥1.66bn | ¥1.58bn | ¥1.51bn | ¥1.40bn | ¥1.34bn |
Financial ratios
Data as of 2 Oct 2026
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 69.7% | 64.8% | 63.3% | 66.3% | 58.2% | 57.5% | — | — |
| Operating margin | 28.0% | 21.7% | 12.9% | 7.3% | -38.6% | -39.8% | — | — |
| Net margin | 32.7% | 25.7% | 22.9% | -36.5% | -40.0% | -52.9% | — | — |
| Return on equity | 17.8% | 16.4% | 14.8% | -26.9% | -18.9% | -19.6% | — | — |
| Return on assets | 15.3% | 13.5% | 11.5% | -20.2% | -15.2% | -17.3% | — | — |
| Free cash flow yield | 3.1% | 2.2% | 1.4% | — | — | -1.7% | -5.4% | -2.2% |
| Revenue growth | 3.7% | 18.7% | 2.8% | 22.7% | 7.4% | 4.6% | — | — |
| Earnings growth | 32.1% | 33.4% | -164.4% | 12.0% | -18.8% | -52.3% | — | — |
| Current ratio | 5.68x | 4.94x | 4.90x | 4.62x | 4.95x | 7.76x | — | — |
| Debt to equity | 0.10x | 0.13x | 0.19x | 0.22x | 0.17x | 0.06x | — | — |
| Equity ratio | 85.5% | 82.0% | 78.1% | 75.2% | 80.2% | 88.6% | — | — |
| Interest coverage | 211.01x | 166.79x | 93.22x | 54.40x | -390.00x | -320.37x | — | — |
| R&D as a share of sales | 11.9% | 12.3% | 15.9% | 22.6% | 29.1% | 44.3% | — | — |
| Buybacks as a share of market value | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 8.1% | 10.8% | 3.4% |
| Operating income | 68.9% | — | — |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Gross margin | 67.3% | 66.2% | 64.0% | 60.8% |
| Operating margin | 24.9% | 18.3% | 3.4% | -34.1% |
| Net margin | 29.3% | 13.2% | -2.1% | -37.1% |
Valuation history
At each fiscal year end
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings | 27.9 | 70.9 | 14.8 | -10.2 | -6.9 | -6.4 | -4.6 | -22.9 | -62.0 | -1.7 |
| Price to sales | 9.2 | 18.2 | 3.4 | 3.7 | 2.8 | 3.4 | 5.4 | 4.9 | 4.3 | 4.9 |
Dividends and splits
Per share, in the currency the company pays
Paid for 0 years. Last went ex-dividend on 30 Mar 2026.
| FY2026 | FY2014 | |
|---|---|---|
| Paid in the year | 6.00 | 5.00 |
- 10-for-1 split · 26 Sept 2013
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.